Abstract
In response to various growth factors, hormones or cytokines, arachidonic acid can be mobilized from phospholipids pools and converted to bioactive eicosanoids through cyclooxygenase (COX), lipoxygenase (LOX) or P-450 epoxygenase pathway. The COX pathway generates five major prostanoids (prostaglandin D2, prostaglandin E2, prostaglandin F2α, prostaglandin I2 and thromboxane A2) that play important roles in diverse biological processes. Studies suggest that different prostanoids and their own synthase can play distinct roles in tumor progression and cancer metastasis. COX-2 and PGE2 synthase have been most well documented in the regulation of various aspects of tumor progression and metastasis. PGE2, for example, can stimulate angiogenesis or other signaling pathways by binding to its receptors termed EPs. Therefore, targeting downstream prostanoids may provide a new avenue to impede tumor progression. In this review, aberrant expression and functions of several prostanoid synthetic enzymes in cancer will be discussed. The possible regulation of tumor progression by prostaglandins and their receptors will also be discussed.
Similar content being viewed by others
References
Nie, D., Che, M., Grignon, D., Tang, K., & Honn, K. V. (2001). Role of eicosanoids in prostate cancer progression. Cancer and Metastasis Reviews, 20, 195–06.
Shinohara, H., Balboa, M. A., Johnson, C. A., Balsinde, J., & Dennis, E. A. (1999). Regulation of delayed prostaglandin production in activated P388D1 macrophages by group IV cytosolic and group V secretory phospholipase A2s. Journal of Biological Chemistry, 274, 12263–2268.
Hara, S., Miyata, A., Yokoyama, C., Inoue, H., Brugger, R., Lottspeich, F., et al. (1994). Isolation and molecular cloning of prostacyclin synthase from bovine endothelial cells. Journal of Biological Chemistry, 269, 19897–9903.
Kuwamoto, S., Inoue, H., Tone, Y., Izumi, Y., & Tanabe, T. (1997). Inverse gene expression of prostacyclin and thromboxane synthases in resident and activated peritoneal macrophages. FEBS Letters, 409, 242–46.
Suzuki, T., Watanabe, K., Kanaoka, Y., Sato, T., & Hayaishi, O. (1997). Induction of hematopoietic prostaglandin D synthase in human megakaryocytic cells by phorbol ester. Biochemical and Biophysical Research Communications, 241, 288–93.
Jakobsson, P. J., Thoren, S., Morgenstern, R., & Samuelsson, B. (1999). Identification of human prostaglandin E synthase: A microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proceedings of the National Academy of Sciences of the United States of America, 96, 7220–225.
Bonvalet, J. P., Pradelles, P., & Farman, N. (1987). Segmental synthesis and actions of prostaglandins along the nephron. American Journal of Physiology, 253, F377–87.
Smith, W. L. (1992). Prostanoid biosynthesis and mechanisms of action. American Journal of Physiology, 263, F181–91.
Narumiya, S., Sugimoto, Y., & Ushikubi, F. (1999). Prostanoid receptors: structures, properties, and functions. Physiological Reviews, 79, 1193–226.
Chandrasekharan, N. V., Dai, H., Roos, K. L., Evanson, N. K., Tomsik, J., Elton, T. S., et al. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression. Proceedings of the National Academy of Sciences of the United States of America, 99, 13926–3931.
Park, J. Y., Pillinger, M. H., & Abramson, S. B. (2006). Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases. Clinical Immunology, 119, 229–40.
Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., & Tarnawski, A. S. (2002). Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Medicine, 8, 289–93.
Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van De Putte, L. B., et al. (1998). Cyclooxygenase in biology and disease. FASEB Journal, 12, 1063–073.
Gupta, R. A., Tejada, L. V., Tong, B. J., Das, S. K., Morrow, J. D., Dey, S. K., et al. (2003). Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Research, 63, 906–11.
Patrignani, P., Tacconelli, S., Sciulli, M. G., & Capone, M. L. (2005). New insights into COX-2 biology and inhibition. Brain Research Brain Research Reviews, 48, 352–59.
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & DuBois, R. N. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183–188.
DuBois, R. N., Radhika, A., Reddy, B. S., & Entingh, A. J. (1996). Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology, 110, 1259–262.
Molina, M. A., Sitja-Arnau, M., Lemoine, M. G., Frazier, M. L., & Sinicrope, F. A. (1999). Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Research, 59, 4356–362.
Tucker, O. N., Dannenberg, A. J., Yang, E. K., Zhang, F., Teng, L., Daly, J. M., et al. (1999). Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Research, 59, 987–90.
Dubinett, S. M., Sharma, S., Huang, M., Dohadwala, M., Pold, M., & Mao, J. T. (2003). Cyclooxygenase-2 in lung cancer. Progress in Experimental Tumor Research, 37, 138–62.
Achiwa, H., Yatabe, Y., Hida, T., Kuroishi, T., Kozaki, K., Nakamura, S., et al. (1999). Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clinical Cancer Research, 5, 1001–005.
Hida, T., Yatabe, Y., Achiwa, H., Muramatsu, H., Kozaki, K., Nakamura, S., et al. (1998). Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Research, 58, 3761–764.
Takahashi, T., Kozaki, K., Yatabe, Y., Achiwa, H., & Hida, T. (2002). Increased expression of COX-2 in the development of human lung cancers. Journal of Environmental Pathology, Toxicology and Oncology, 21, 177–81.
Uefuji, K., Ichikura, T., Mochizuki, H., & Shinomiya, N. (1998). Expression of cyclooxygenase-2 protein in gastric adenocarcinoma. Journal of Surgical Oncology, 69, 168–72.
Uefuji, K., Ichikura, T., & Mochizuki, H. (2001). Expression of cyclooxygenase-2 in human gastric adenomas and adenocarcinomas. Journal of Surgical Oncology, 76, 26–0.
Soydan, A. S., Gaffen, J. D., Weech, P. K., Tremblay, N. M., Kargman, S., O’Neill, G., et al. (1997). Cytosolic phospholipase A2, cyclo-oxygenases and arachidonate in human stomach tumours. European Journal of Cancer, 33, 1508–512.
Kundu, N., Yang, Q., Dorsey, R., & Fulton, A. M. (2001). Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. International Journal of Cancer, 93, 681–86.
Barnes, N., Haywood, P., Flint, P., Knox, W. F., & Bundred, N. J. (2006). Surviving expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. British Journal of Cancer, 94, 253–58.
Tang, D. W., Lin, S. C., Chang, K. W., Chi, C. W., Chang, C. S., & Liu, T. Y. (2003). Elevated expression of cyclooxygenase (COX)-2 in oral squamous cell carcinoma-evidence for COX-2 induction by areca quid ingredients in oral keratinocytes. Journal of Oral Pathology & Medicine, 32, 522–29.
Zimmermann, K. C., Sarbia, M., Weber, A. A., Borchard, F., Gabbert, H. E., & Schror, K. (1999). Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Research, 59, 198–04.
Lee, L. M., Pan, C. C., Cheng, C. J., Chi, C. W., & Liu, T. Y. (2001). Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. Anticancer Research, 21, 1291–294.
Kirschenbaum, A., Klausner, A. P., Lee, R., Unger, P., Yao, S., Liu, X. H., et al. (2000). Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology, 56, 671–76.
Kirschenbaum, A., Liotta, D. R., Yao, S., Liu, X. H., Klausner, A. P., Unger, P., et al. (2000). Immunohistochemical localization of cyclooxygenase-1 and cyclooxygenase-2 in the human fetal and adult male reproductive tracts. Journal of Clinical Endocrinology and Metabolism, 85, 3436–441.
Kandil, H. M., Tanner, G., Smalley, W., Halter, S., Radhika, A., & Dubois, R. N. (2001). Cyclooxygenase-2 expression in Barrett’s esophagus. Digestive Diseases and Sciences, 46, 785–89.
Hasegawa, K., Ohashi, Y., Ishikawa, K., Yasue, A., Kato, R., Achiwa, Y., et al. (2005). Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor. International Journal of Oncology, 26, 1419–428.
Sheng, H., Williams, C. S., Shao, J., Liang, P., DuBois, R. N., & Beauchamp, R. D. (1998). Induction of cyclooxygenase-2 by activated Ha-ras oncogene in Rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. Journal of Biological Chemistry, 273, 22120–2127.
Subbaramaiah, K., Altorki, N., Chung, W. J., Mestre, J. R., Sampat, A., & Dannenberg, A. J. (1999). Inhibition of cyclooxygenase-2 gene expression by p53. Journal of Biological Chemistry, 274, 10911–0915.
Tsujii, M., Kawano, S., & DuBois, R. N. (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences of the United States of America, 94, 3336–340.
Attiga, F. A., Fernandez, P. M., Weeraratna, A. T., Manyak, M. J., & Patierno, S. R. (2000). Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Research, 60, 4629–637.
Nardone, G., Rocco, A., Vaira, D., Staibano, S., Budillon, A., Tatangelo, F., et al. (2004). Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: A molecular pathway of H pylori-related gastric carcinogenesis. Journal of Pathology, 202, 305–12.
Tanioka, T., Nakatani, Y., Semmyo, N., Murakami, M., & Kudo, I. (2000). Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. Journal of Biological Chemistry, 275, 32775–2782.
Murakami, M., & Kudo, I. (2004). Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Progress in Lipid Research, 43, 3–5.
Forsberg, L., Leeb, L., Thoren, S., Morgenstern, R., & Jakobsson, P. (2000). Human glutathione dependent prostaglandin E synthase: Gene structure and regulation. FEBS Letters, 471, 78–2.
Murakami, M., Naraba, H., Tanioka, T., Semmyo, N., Nakatani, Y., Kojima, F., et al. (2000). Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. Journal of Biological Chemistry, 275, 32783–2792.
Guan, Y., Zhang, Y., Schneider, A., Riendeau, D., Mancini, J. A., Davis, L., et al. (2001). Urogenital distribution of a mouse membrane-associated prostaglandin E(2) synthase. American Journal of Physiology Renal Physiology, 281, F1173’F1177.
Filion, F., Bouchard, N., Goff, A. K., Lussier, J. G., & Sirois, J. (2001). Molecular cloning and induction of bovine prostaglandin E synthase by gonadotropins in ovarian follicles prior to ovulation in vivo. Journal of Biological Chemistry, 276, 34323–4330.
Murakami, M., Nakatani, Y., Tanioka, T., & Kudo, I. (2002). Prostaglandin E synthase. Prostaglandins & Other Lipid Mediators, 68–9, 383–99.
Watanabe, K., Kurihara, K., & Suzuki, T. (1999). Purification and characterization of membrane-bound prostaglandin E synthase from bovine heart. Biochimica Et Biophysica Acta, 1439, 406–14.
Backlund, M. G., Mann, J. R., Holla, V. R., Buchanan, F. G., Tai, H. H., Musiek, E. S., et al. (2005). 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. Journal of Biological Chemistry, 280, 3217–223.
Yan, M., Rerko, R. M., Platzer, P., Dawson, D., Willis, J., Tong, M., et al. (2004). 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proceedings of the National Academy of Sciences of the United States of America, 101, 17468–7473.
Yoshimatsu, K., Altorki, N. K., Golijanin, D., Zhang, F., Jakobsson, P. J., Dannenberg, A. J., et al. (2001). Inducible prostaglandin E synthase is overexpressed in non-small cell lung cancer. Clinical Cancer Research, 7, 2669–674.
Wang, D., & DuBois, R. N. (2004). Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proceedings of the National Academy of Sciences of the United States of America, 101, 415–16.
Chang, S. H., Liu, C. H., Conway, R., Han, D. K., Nithipatikom, K., Trifan, O. C., et al. (2004). Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 101, 591–96.
Majima, M., Hayashi, I., Muramatsu, M., Katada, J., Yamashina, S., & Katori, M. (2000). Cyclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. British Journal of Pharmacology, 130, 641–49.
Helliwell, R. J., Adams, L. F., & Mitchell, M. D. (2004). Prostaglandin synthases: Recent developments and a novel hypothesis. Prostaglandins, Leukotrienes and Essential Fatty Acids, 70, 101–13.
Watanabe, K. (2002). Prostaglandin F synthase. Prostaglandins & Other Lipid Mediators, 68–9, 401–07.
Suzuki-Yamamoto, T., Toida, K., Tsuruo, Y., Watanabe, K., & Ishimura, K. (2000). Immunocytochemical localization of lung-type prostaglandin F synthase in the rat spinal cord. Brain Research, 877, 391–95.
Madore, E., Harvey, N., Parent, J., Chapdelaine, P., Arosh, J. A., & Fortier, M. A. (2003). An aldose reductase with 20 alpha-hydroxysteroid dehydrogenase activity is most likely the enzyme responsible for the production of prostaglandin f2 alpha in the bovine endometrium. Journal of Biological Chemistry, 278, 11205–1212.
Nishizawa, M., Nakajima, T., Yasuda, K., Kanzaki, H., Sasaguri, Y., Watanabe, K., et al. (2000). Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with three aldo-keto reductase genes. Genes Cells, 5, 111–25.
Narko, K., Ritvos, O., & Ristimaki, A. (1997). Induction of cyclooxygenase-2 and prostaglandin F2alpha receptor expression by interleukin-1beta in cultured human granulosa-luteal cells. Endocrinology, 138, 3638–644.
Sales, K. J., Milne, S. A., Williams, A. R., Anderson, R. A., & Jabbour, H. N. (2004). Expression, localization, and signaling of prostaglandin F2 alpha receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogen-activated protein kinase signaling pathways. Journal of Clinical Endocrinology and Metabolism, 89, 986–93.
Sales, K. J., List, T., Boddy, S. C., Williams, A. R., Anderson, R. A., Naor, Z., et al. (2005). A novel angiogenic role for prostaglandin F2alpha-FP receptor interaction in human endometrial adenocarcinomas. Cancer Research, 65, 7707–716.
Sales, K. J., Maudsley, S., & Jabbour, H. N. (2004). Elevated prostaglandin EP2 receptor in endometrial adenocarcinoma cells promotes vascular endothelial growth factor expression via cyclic 3–5–adenosine monophosphate-mediated transactivation of the epidermal growth factor receptor and extracellular signal-regulated kinase 1/2 signaling pathways. Molecular Endocrinology, 18, 1533–545.
Reiter, R. A., Peskar, B. A., & Sinzinger, H. (2004). Defects in the prostaglandin system—what is known? Prostaglandins, Leukotrienes and Essential Fatty Acids, 71, 347–50.
Nakayama, T. (2005). Prostacyclin synthase gene: Genetic polymorphisms and prevention of some cardiovascular diseases. Current Medicinal Chemistry Cardiovascular Hematology Agents, 3, 157–64.
Lim, H., & Dey, S. K. (2002). A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology, 143, 3207–210.
Gupta, R. A., Tan, J., Krause, W. F., Geraci, M. W., Willson, T. M., Dey, S. K., et al. (2000). Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America, 97, 13275–3280.
Tong, B. J., Tan, J., Tajeda, L., Das, S. K., Chapman, J. A., DuBois, R. N., et al. (2000). Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia, 2, 483–90.
Tanabe, T., & Ullrich, V. (1995). Prostacyclin and thromboxane synthases. Journal of Lipid Mediators Cell Signal, 12, 243–55.
Miyata, A., Yokoyama, C., Ihara, H., Bandoh, S., Takeda, O., Takahashi, E., et al. (1994). Characterization of the human gene (TBXAS1) encoding thromboxane synthase. European Journal of Biochemistry, 224, 273–79.
Lee, K. D., Baek, S. J., & Shen, R. F. (1994). Cloning and characterization of the human thromboxane synthase gene promoter. Biochemical and Biophysical Research Communications, 201, 379–87.
Nanayama, T., Hara, S., Inoue, H., Yokoyama, C., & Tanabe, T. (1995). Regulation of two isozymes of prostaglandin endoperoxide synthase and thromboxane synthase in human monoblastoid cell line U937. Prostaglandins, 49, 371–82.
Kajita, S., Ruebel, K. H., Casey, M. B., Nakamura, N., & Lloyd, R. V. (2005). Role of COX-2, thromboxane A2 synthase, and prostaglandin I2 synthase in papillary thyroid carcinoma growth. Modern Pathology, 18, 221–27.
Pinto, S., Gori, L., Gallo, O., Boccuzzi, S., Paniccia, R., & Abbate, R. (1993). Increased thromboxane A2 production at primary tumor site in metastasizing squamous cell carcinoma of the larynx. Prostaglandins, Leukotrienes and Essential Fatty Acids, 49, 527–30.
Bryant, J. (1994). Correlation between metastatic patterns in renal cell carcinoma and tissue distribution of thromboxane synthetase. Acta oncológica, 33, 708–09.
Nie, D., Che, M., Zacharek, A., Qiao, Y., Li, L., Li, X., et al. (2004). Differential expression of thromboxane synthase in prostate carcinoma: Role in tumor cell motility. American Journal of Pathology, 164, 429–39.
Giese, A., Hagel, C., Kim, E. L., Zapf, S., Djawaheri, J., Berens, M. E., et al. (1999). Thromboxane synthase regulates the migratory phenotype of human glioma cells. Neuro-Oncology, 1, 3–3.
McDonough, W., Tran, N., Giese, A., Norman, S. A., & Berens, M. E. (1998). Altered gene expression in human astrocytoma cells selected for migration: I. Thromboxane synthase. Journal of Neuropathology and Experimental Neurology, 57, 449–55.
Rodrigues, S., Nguyen, Q. D., Faivre, S., Bruyneel, E., Thim, L., Westley, B., et al. (2001). Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB Journal, 15, 1517–528.
Yoshizato, K., Zapf, S., Westphal, M., Berens, M. E., & Giese, A. (2002). Thromboxane synthase inhibitors induce apoptosis in migration-arrested glioma cells. Neurosurgery, 50, 343–54.
Robert, A., Nezamis, J. E., Lancaster, C., & Hanchar, A. J. (1979). Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology, 77, 433–43.
Takafuji, V. A., Evans, A., Lynch, K. R., & Roche, J. K. (2002). PGE(2) receptors and synthesis in human gastric mucosa: perturbation in cancer. Prostaglandins, Leukotrienes and Essential Fatty Acids, 66, 71–1.
Marnett, L. J., & DuBois, R. N. (2002). COX-2: A target for colon cancer prevention. Annual Review of Pharmacology and Toxicology, 42, 55–0.
Forman, B. M., Chen, J., & Evans, R. M. (1996). The peroxisome proliferator-activated receptors: Ligands and activators. Annals of the New York Academy of Sciences, 804, 266–75.
Sonoshita, M., Takaku, K., Oshima, M., Sugihara, K., & Taketo, M. M. (2002). Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Research, 62, 6846–849.
Chell, S. D., Witherden, I. R., Dobson, R. R., Moorghen, M., Herman, A. A., Qualtrough, D., et al. (2006). Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Research, 66, 3106–113.
Castellone, M. D., Teramoto, H., Williams, B. O., Druey, K. M., & Gutkind, J. S. (2005). Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science, 310, 1504–510.
Sheng, H., Shao, J., Washington, M. K., & DuBois, R. N. (2001). Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. Journal of Biological Chemistry, 276, 18075–8081.
Dorn, G. W., 2nd, Sens, D., Chaikhouni, A., Mais, D., & Halushka, P. V. (1987). Cultured human vascular smooth muscle cells with functional thromboxane A2 receptors: Measurement of U46619-induced 45calcium efflux. Circulation Research, 60, 952–56.
Pakala, R., Willerson, J. T., & Benedict, C. R. (1997). Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation, 96, 2280–286.
FitzGerald, G. A. (1991). Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists. American Journal of Cardiology, 68, 11B–5B.
Ali, S., Davis, M. G., Becker, M. W., & Dorn, G. W., 2nd (1993). Thromboxane A2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. Journal of Biological Chemistry, 268, 17397–7403.
Hirata, M., Hayashi, Y., Ushikubi, F., Yokota, Y., Kageyama, R., Nakanishi, S., et al. (1991). Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature, 349, 617–20.
Raychowdhury, M. K., Yukawa, M., Collins, L. J., McGrail, S. H., Kent, K. C., & Ware, J. A. (1995). Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. Journal of Biological Chemistry, 270, 7011.
Miggin, S. M., & Kinsella, B. T. (1998). Expression and tissue distribution of the mRNAs encoding the human thromboxane A2 receptor (TP) alpha and beta isoforms. Biochimica Et Biophysica Acta, 1425, 543–59.
Breyer, R. M., Bagdassarian, C. K., Myers, S. A., & Breyer, M. D. (2001). Prostanoid receptors: Subtypes and signaling. Annual Review of Pharmacology and Toxicology, 41, 661–90.
Needleman, P., Wyche, A., & Raz, A. (1979). Platelet and blood vessel arachidonate metabolism and interactions. Journal of Clinical Investigation, 63, 345–49.
Cogolludo, A., Moreno, L., Bosca, L., Tamargo, J., & Perez-Vizcaino, F. (2003). Thromboxane A2-induced inhibition of voltage-gated K+ channels and pulmonary vasoconstriction: role of protein kinase Czeta. Circulation Research, 93, 656–63.
Sullivan, P., & Smyth, E. M. (2002). Heterodimerization of the a and b isoforms of the human thromboxane receptor. Arteriosclerosis Thrombosis Vascular Biology, 22, 878.
Chen, G. G., Lee, T. W., Yip, J. H., Xu, H., Lee, I. K., Mok, T. S., et al. (2005). Increased thromboxane B(2) levels are associated with lipid peroxidation and Bcl-2 expression in human lung carcinoma. Cancer Letters.
Watkins, G., Douglas-Jones, A., Mansel, R. E., & Jiang, W. G. (2005). Expression of thromboxane synthase, TBXAS1 and the thromboxane A2 receptor, TBXA2R, in human breast cancer. International Seminars Surgical Oncology, 2, 23.
Ristimaki, A., Sivula, A., Lundin, J., Lundin, M., Salminen, T., Haglund, C., et al. (2002). Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Research, 62, 632–35.
Liu, C. H., Chang, S. H., Narko, K., Trifan, O. C., Wu, M. T., Smith, E., et al. (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. Journal of Biological Chemistry, 276, 18563–8569.
Johnson, T. W., Anderson, K. E., Lazovich, D., & Folsom, A. R. (2002). Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Cancer Epidemiology Biomarkers & Prevention, 11, 1586–591.
Harris, R. E., Chlebowski, R. T., Jackson, R. D., Frid, D. J., Ascenseo, J. L., Anderson, G., et al. (2003). Breast cancer and nonsteroidal anti-inflammatory drugs: Prospective results from the Women’s Health Initiative. Cancer Research, 63, 6096–101.
Blair, C. K., Sweeney, C., Anderson, K. E., & Folsom, A. R. (2006). NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Research and Treatment.
Ratliff, T. L. (2005). Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (review). Journal of Urology, 174, 787–88.
Howe, L. R., Subbaramaiah, K., Brown, A. M., & Dannenberg, A. J. (2001). Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine Related Cancer, 8, 97–14.
Takeuchi, K., Tanaka, A., Hayashi, Y., & Yokota, A. (2005). COX inhibition and NSAID-induced gastric damage—roles in various pathogenic events. Current Topics in Medicinal Chemistry, 5, 475–86.
Wang, D., & Dubois, R. N. (2005). Prostaglandins and cancer. Gut, 55, 115–22.
Lenzer, J. (2005). FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ, 330, 440.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, MT., Honn, K.V. & Nie, D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 26, 525–534 (2007). https://doi.org/10.1007/s10555-007-9096-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-007-9096-5